Voor het eerst maken biosensing-oordopjes gebruik van externe, zeer nauwkeurige en longitudinale EEG-gegevens om neurologische aandoeningen te diagnosticeren en te verbeteren

CHICAGO–(BUSINESS WIRE)– NextSense, het fundament van de gezondheid van de hersenen, kwam onverwachts met een aankondiging van de jaarlijkse bijeenkomst van de AES (American Epilepsy Society) in Chicago, waar NextSense en zijn partners de resultaten presenteren van hun onderzoek naar epileptische aanvallen detectie voor het eerst aan peers in de academische wereld en de industrie.

NextSense ontgrendelt hersengezondheid met real-world data-inzichten en praktische, wetenschappelijke wijsheid voor het dagelijks leven. Traditionele technologie voor het monitoren van de hersengezondheid, zoals EEG-machines en polysomnogrammen, zijn te omvangrijk voor thuisgebruik, waardoor patiënten ter observatie in ziekenhuizen of slaapklinieken moeten overnachten. De hoge zorgkosten en het gebrek aan comfort van deze apparaten maken langdurige en continue monitoring bijna onmogelijk. Deze gegevens zijn niet alleen gebaseerd op een enkel tijdsbestek, ze observeren wat allesbehalve een gewone nachtrust is. En voor iedereen die met epilepsie leeft, maakt de onvoorspelbaarheid van aanvallen directe observatie en hoogwaardige gegevensverzameling buitengewoon zeldzaam.

NextSense Emerges to Unlock Brain Health with Key Partners UCB, Heraeus, UC San Diego, and Emory University

For the first time, biosensing earbuds leverage remote, highly-accurate and longitudinal EEG data to diagnose and improve management of neurological disorders

CHICAGO–(BUSINESS WIRE)– NextSense, the foundation of brain health, came out of stealth with an announcement made from the AES (American Epilepsy Society) Annual Meeting in Chicago, where NextSense and its partners are presenting the results of their research on seizure detection to peers in academia and industry for the first time.

NextSense unlocks brain health with real world data insights and practical, scientific wisdom for daily living. Traditional brain health monitoring technology like EEG machines and polysomnograms are too bulky for home use, requiring patients to stay overnight at hospitals or sleep study clinics for observation. The high cost of care and lack of comfort of these devices makes long-term and continuous monitoring nearly impossible. Not only are these data based on a single timeframe, they observe what is anything but an ordinary night’s sleep. And for anyone living with epilepsy, the unpredictability of seizures makes direct observation and high-quality data-gathering exceedingly rare.

The NextSense platform starts with longitudinal EEG data collected at the point of experience with biosensing earbuds that can be worn comfortably at night and as-needed throughout the day. The company envisions combining that data with environmental and behavioral patterns collected from smart devices and timely analysis from its team of neuroscientists to help doctors identify triggers, diagnose certain conditions and tailor treatment and medication recommendations in real-time.

At the AES Annual Meeting, NextSense detailed for the first time its key relationship with biopharma partner UCB. The company also revealed research and IP agreements with both Heraeus and UC San Diego, as well as a multi-dimensional collaboration with researchers at Emory University.

“We believe that technologies that enable earlier detection of seizures and improve the coordination of care for people living with epilepsy complement UCB’s strong heritage in epilepsy and portfolio of medicines,” said Colin Lake, Vice President of Digital Business Transformation for Neurology at UCB. “Being able to access meaningful data that NextSense can provide will allow us to capture insights and solve complex disease questions that will help epilepsy patients on their care journey achieve better outcomes.”

Each pharma and biotech company has partnered with NextSense to study how neurologists can better calibrate and manage treatment plans for epilepsy, sleep, and potentially other CNS disorders, using the company’s platform.

Emory University’s Brain Health Center, led by world-renowned physician-scientist Allan Levey, is the site of multiple NextSense studies and its first two clinical trials.

“We’re excited for what this partnership means for both NextSense and Emory Brain Health,” said Allan Levey, Founding Director of Goizueta Institute at Emory Brain Health. “Our work alongside Emory’s Department of Biomedical Informatics signifies a notable step forward toward chronic ambulatory monitoring of brain physiology via EEG. With their earbuds allowing access for monitoring data over much longer periods of time, the initial findings and foundational work are very promising and showing how their efforts and technology has significant potential to revolutionize the approach to diagnosing and treating many neurological disorders in the future.”

“We’ve assembled a dream team of collaborators,” said Jonathan Berent, Founder and CEO of NextSense. “It is a personal and professional thrill to partner with these innovators at the very top of their field. Our partners have worked with us shoulder-to-shoulder to methodically pursue what many people said was impossible. We are beyond excited to begin to show the world what we have achieved, starting with the scientific community at AES.”

NextSense is continuing to enroll participants in clinical trials focused on epilepsy and sleep. Eventually, the company hopes to leverage the long-term data collected to help establish biomarkers for brain health.

“Whether someone is living with epilepsy, struggling to stay alert, or seeking an elusive diagnosis for a neurological condition, we’re offering hope,“ said Jen Dwyer, Medical Director of NextSense. “We see our members from every angle, and we understand their unique pain points. We’re working towards a world where those who suffer from these conditions don’t have to choose between comfort and accuracy. And we’re just getting started.”

About NextSense, Inc.

NextSense is the foundation of a healthy brain.

We unlock brain health with real-world data insights and practical, scientific wisdom for daily living. Whether you are struggling to stay alert, living with something like epilepsy, seeking an elusive diagnosis for a neurological condition, we can help.

We are a passionate team of neuroscientists and venture operators on a mission to catalyze brain health in both science and culture.

To learn more, please visit: www.nextsense.io

View source version on businesswire.com: https://www.businesswire.com/news/home/20211203005110/en/

Contacts

Shannia Coley

Shannia@jones-dilworth.com
443-471-6830